Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for INCY, sign up here.
Income Statement
Revenue
$3.7bn
Gross Profit
$3.4bn
Earning before Tax
$834.2m
Net Income
$597.6m
Net Income Common Shareholders
$597.6m
EPS
2.67
Balance Sheet
Cash
$3.2bn
Debt
$32.6m
Assets
$6.8bn
Liabilities
$1.6bn
Equity
$5.2bn
Enterprise Value
$10.9bn
Cash Flow Statement
Net Cash from Operations
$496.5m
Net Cash from Investing
$-0.2bn
Net Cash from Financing
$-20.0m
Net Cash Flow
$262.1m
Free Cash Flow
$464.0m
Free Cash Flow per Share
$2.08
Metrics
Price to Equity
23.55
Price to Equity (Damodaran)
23.52
Price to Book
2.71
Net Margin
0.16
Return on Equity
0.12
Return on Sales
0.23
Get immediate access to 5-years of reference grade data for INCY for free.
Sign upIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Company Info
Industry
Biotechnology
Employees
2,324
Address
1801 Augustine Cut-Off
Wilmington, DE 19803
United States
Phone
302 498 6700
Website
Last Updated
2024-02-08
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.